Basit öğe kaydını göster

dc.contributor.authorHanberger H.
dc.contributor.authorAntonelli M.
dc.contributor.authorHolmbom M.
dc.contributor.authorLipman J.
dc.contributor.authorPickkers P.
dc.contributor.authorLeone M.
dc.contributor.authorZakynthinos E.
dc.date.accessioned2020-06-21T09:37:23Z
dc.date.available2020-06-21T09:37:23Z
dc.date.issued2014
dc.identifier.issn1471-2334
dc.identifier.urihttps://doi.org/10.1186/1471-2334-14-513
dc.identifier.urihttps://hdl.handle.net/20.500.12712/4732
dc.descriptionPubMed: 25245620en_US
dc.description.abstractBackground: Antimicrobial resistance is an increasing concern in ICUs worldwide. Infection with an antibiotic resistant (ABR) strain of an organism is associated with greater mortality than infection with the non-resistant strain, but there are few data assessing whether being admitted to an intensive care unit (ICU) with high levels of antimicrobial resistance is associated with a worse outcome than being admitted to an ICU with low rates of resistance. The aim of this study was, therefore, to compare the characteristics of infections and antibiotic treatments and patient outcomes in patients admitted to ICUs in countries considered as having high levels of antibiotic resistance and those admitted to ICUs in countries considered as having low levels of antibiotic resistance.Methods: Data from the large, international EPIC II one-day point prevalence study on infections in patients hospitalized in ICUs were used. For the current study, we compared the data obtained from patients from two groups of countries: countries with reported MRSA rates of ? 25% (highABR: Greece, Israel, Italy, Malta, Portugal, Spain, and Turkey) and countries with MRSA rates of < 5% (lowABR: Denmark, Finland, Netherlands, Norway, and Sweden).Results: On the study day, 1187/2204 (53.9%) patients in the HighABR ICUs were infected and 255/558 (45.7%) in the LowABR ICUs (P < 0.01). Patients in the HighABR ICUs were more severely ill than those in the LowABR ICUs, as reflected by a higher SAPS II score (35.6 vs 32.7, P < 0.05) and had longer median ICU (12 days vs 5 days) and hospital (24 days vs 16 days) lengths of stay. They also had higher crude ICU (20.0% vs 15.4%) and hospital (27.0% vs 21.5%) mortality rates (both P < 0.05). However, after multivariable adjustment and matched pair analysis there were no differences in ICU or hospital mortality rates between High or LowABR ICU patients overall or among those with infections.Conclusions: Being hospitalized in an ICU in a region with high levels of antimicrobial resistance is not associated per se with a worse outcome. © 2014 Hanberger et al.; licensee BioMed Central Ltd.en_US
dc.language.isoengen_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.isversionof10.1186/1471-2334-14-513en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAntibioticen_US
dc.subjectCritically illen_US
dc.subjectInfectionen_US
dc.subjectResistanceen_US
dc.titleInfections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levelsen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume14en_US
dc.identifier.issue1en_US
dc.relation.journalBMC Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster